Home
Live Updates
Telitacicept Efficacious, Safe in Treating Rheumatoid Arthritis Patients with Inadequate MTX Response : comparemela.com
Telitacicept Efficacious, Safe in Treating Rheumatoid Arthritis Patients with Inadequate MTX Response
In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.
Related Keywords
Pennsylvania ,
United States ,
San Diego ,
California ,
Qing Zuraw ,
Remegen Biosciences ,
American College Of Rheumatology ,
American College Of Rheumatology Convergence ,
American College ,
Human Recombinant Fusion Protein Targeting ,
Neutralizingb Lymphocyte Stimulator ,
Proliferation Inducing Ligand ,
Rheumatoid Arthritis ,
Inadequate Response ,
Rheumatology Convergence ,
Racr ,
Telitacicept ,
Mtx ,
comparemela.com © 2020. All Rights Reserved.